Expect stronger growth in second half of FY20: Kiran Mazumdar Shaw, Biocon
  • WebDesk BTVI
  • Jul 26 2019

Kiran Mazumdar Shaw, CMD of Biocon, discusses what led to the stellar growth in Q1. She says small molecules, biologics, & research services have all contributed to growth in the first quarter, and adds that the firm expects even stronger growth in the second half of the fiscal. She says generics business has taken off well in the US, which has contributed to the numbers. She says the firm expects to end FY20 on a very robust note.